Full Year 2024 Angle PLC Earnings Call Transcript
Key Points
- ANGLE PLC (ANPCY) achieved a 31% growth in revenues for 2024 compared to 2023, despite adverse market conditions.
- The company successfully secured three large pharma contracts and one large biopharma contract, with all progressing well and concluding successfully.
- ANGLE PLC (ANPCY) developed a new DNA dual analysis method, offering unique insights by analyzing both living cancer cells and fragments of dead cells.
- The company reduced operating expenditure by 21%, contributing to a 29% reduction in losses.
- ANGLE PLC (ANPCY) has over 100 peer-reviewed publications from independent cancer centers validating the effectiveness of its Parsortix system.
- There are delays in decision-making from large pharma companies, affecting the timing of potential contracts.
- The company faces challenges due to the tightening funding environment, impacting smaller biopharma companies and delaying some projects.
- Uncertainty in research funding, particularly in the US, is causing delays in purchasing decisions from research institutions.
- The company is experiencing delays in the procurement process in Europe, even when they are the preferred vendor.
- ANGLE PLC (ANPCY) faces competition from established methods like circulating tumor DNA (CT-DNA) analysis, requiring significant market education efforts.
Good morning everybody and welcome to Angle's preliminary presentation for 2024. I'm pleased to see a very good turnout, considering it's half term, in the FTI offices, and a warm welcome to those of you who are participating virtually.
It's been a year of substantial progress for Angle in a market that is moving towards us, and I'm looking forward to telling you about the progress that has been made. Our large pharma strategy is now in place. We announced that in the middle of last year. It's firmly in place and it's moving forward well.
This is all about using pastortics to select and monitor patients in trials for pharmaceutical drug development, and that can progress all the way through to companion diagnostics, where the pastortic system could be used to select patients for each drug.
This approach is critical to the new way that drugs are being developed for precision medicine. The new cancer drugs only work for some patients, and it's critical to work out which patients. These kinds of new drugs, such as
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
